Tirzepatide belongs to a new class of medications called dual incretin receptor agonists
1 This is the first real-world report assessing semaglutide in the treatment of non-diabetic IgAN with overweight or obesity, wrote Feng-Lei Si, Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, and colleagues
As the landscape rapidly evolves, the question of the best GLP-1 for weight loss, especially the comparison between oral and injectable semaglutide has never been more relevant
The SURPASS trials are designed to evaluate once-weekly tirzepatide doses of 5 mg, 10 mg, and 15 mg with a dose escalation algorithm: starting dose at 2.5 mg weekly for the first 4 weeks, then dose increment of 2.5 mg every 4 weeks until the maintenance dose of 5 mg, 10 mg, or 15 mg is achieved
Reconstituting too far in advance
Importantly, research suggests DSIP doesn't simply sedate you